Clinical observation of raltitrexed containing regimen for advanced colorectal cancer

VernacularTitle:含雷替曲塞方案治疗进展期结直肠癌的临床观察
Author: Ling CHEN ¹ ; Zengqing GUO ; Xiaojie WANG ; Yu CHEN ; Jiami YU
Author Information

1. 福建省肿瘤医院肿瘤内科
Keywords: Colorectal neoplasms; Drug therapy; Raltitrexed
From: Journal of International Oncology 2017;44(8):583-586
CountryChina
Language:Chinese
Abstract: Objective To observe the clinical efficacy and adverse reactions of raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment.Methods A total of 42 patients with advanced colorectal cancer were treated with raltitrexed containing regimen.The objective response rate (ORR),disease control rate (DCR),median progression-free survival (mPFS) and adverse reactions were evaluated.Results The ORR of the 42 patients was 16.67％,DCR was 80.96％,and mPFS was 4.90 months (95％ CⅠ:2.99-6.81 months).The most of adverse reactions were grade Ⅰ-Ⅱ,including leucopenia (30.95％),thrombocytopenia (2.38％),anemia (40.48％),nausea and vomiting (2.38％),anorexia (4.76％),diarrhea (2.38％),transaminase elevation (47.62％) and fatigue (11.90％).Grade Ⅲ-Ⅳ transaminase elevation was found in only 4.76％ of patients.Conclusion Raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment is effective and well tolerated,and further clinical application is recommended.